Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Global X Lithium & Battery Tech ETF (LIT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Global X Lithium & Battery Tech ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Global X Lithium & Battery Tech ETF trades at $72.99. Which is the better fit depends on your goals.
| ACAD | LIT | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $28.06 | $91.62 |
52-Week Low | $20.06 | $39.41 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
LIT (Global X Lithium & Battery Tech ETF) trades at $76.17, down 0.47% with a bearish technical outlook. The ETF faces selling pressure from moving averages but maintains neutral oscillator readings. Recent news highlights strong momentum driven by energy storage, semiconductors, and EV demand, with the fund returning 125% from last year's lows according to 24/7 Wall Street on June 7, 2026. Key financial ratios remain undisclosed in current data.
Outlook remains mixed with technical weakness offset by strong sector catalysts. Investment opportunity lies in exposure to lithium and battery technology growth, particularly from EV and AI demand. Risks include reliance on Chinese supply chains, regulatory changes, and commodity price volatility. The upcoming dividend of $0.32 per share scheduled for July 2026 provides income potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Global X Lithium & Battery Tech ETF
LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →
